1. Market Research
  2. > Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review

Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic products for the treatment of diseases and disorders in humans and animals. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic diseases, respiratory diseases, immune disorders and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generics through Sandoz. It also offers vaccines and over-the-counter (OTC) products. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company has operations across Asia-Pacific, North America, Europe, Africa, and Latin America. Novartis is headquartered in Basel, Switzerland.

Novartis AG Key Recent Developments

Dec 12, 2016: Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
Nov 16, 2016: Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
Nov 14, 2016: Novartis improves ranking in 2016 Access to Medicine Index
Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Novartis AG - Key Facts 6
Novartis AG - Key Employees 7
Novartis AG - Key Employee Biographies 8
Novartis AG - Major Products and Services 10
Novartis AG - Pharmaceutical Pipeline Products Data 13
Novartis AG, Pipeline Products by Therapy Area 13
Novartis AG, Pipeline Products by Development Phase 14
Novartis AG - History 15
Novartis AG - Company Statement 33
Novartis AG - Locations And Subsidiaries 34
Head Office 34
Other Locations and Subsidiaries 34
Section 2 - Company Analysis 54
Novartis AG - Business Description 54
Novartis AG - Corporate Strategy 55
Novartis AG - SWOT Analysis 56
SWOT Analysis - Overview 56
Novartis AG - Strengths 56
Novartis AG - Weaknesses 57
Novartis AG - Opportunities 58
Novartis AG - Threats 60
Novartis AG - Key Competitors 61
Section 3 - Company Financial Ratios 62
Financial Ratios - Capital Market Ratios 62
Financial Ratios - Annual Ratios 63
Performance Chart 65
Financial Performance 65
Financial Ratios - Interim Ratios 66
Financial Ratios - Ratio Charts 67
Section 4 - Company's Lifesciences Financial Deals and Alliances 68
Novartis AG, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 68
Novartis AG, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 69
Novartis AG, Recent Deals Summary 70
Section 5 - Company's Recent Developments 71
Dec 12, 2016: Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines 71
Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda 72
Nov 16, 2016: Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer 73
Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 75
Sep 15, 2016: Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress 81
Aug 12, 2016: 6 Novartis Korean executives indicted for bribing doctors 82
Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects 83
May 25, 2016: Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event 89
May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors 91
May 18, 2016: Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting 92
Section 6 - Appendix 94
Methodology 94
Ratio Definitions 94
About GlobalData 98
Contact Us 98
Disclaimer 98

List of Tables
Novartis AG, Key Facts 6
Novartis AG, Key Employees 7
Novartis AG, Key Employee Biographies 8
Novartis AG, Major Products and Services 10
Novartis AG, Number of Pipeline Products by Therapy Area 13
Novartis AG, Number of Pipeline Products by Development Stage 14
Novartis AG, History 15
Novartis AG, Subsidiaries 34
Novartis AG, Key Competitors 61
Novartis AG, Ratios based on current share price 62
Novartis AG, Annual Ratios 63
Novartis AG (Cont...1), Annual Ratios 64
Novartis AG, Interim Ratios 66
Novartis AG, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 68
Novartis AG, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 69
Novartis AG, Recent Deals Summary 70
Currency Codes 94
Capital Market Ratios 94
Equity Ratios 95
Profitability Ratios 95
Cost Ratios 96
Liquidity Ratios 96
Leverage Ratios 96
Efficiency Ratios 97

List of Figures
Novartis AG, Pipeline Products by Therapy Area 13
Novartis AG, Pipeline Products by Development Phase 14
Novartis AG, Performance Chart (2011 - 2015) 65
Novartis AG, Ratio Charts 67
Novartis AG, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 68
Novartis AG, Pharmaceuticals and Healthcare, Deals by Type, 2010 to YTD 2016 69

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.